TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2128929

Group type: EXPERIMENTAL
Intervention: Conventional preparation (CP)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Total digestive irrigation (TDI)
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Conventional preparation (CP) with Sennosides
Number of subjects: 1265

Group type: COMPARATOR
Intervention: 2 liters of 10% Mannitol
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Lukewarm water enemas
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Enemas with iodinated polyvidone diluted to 5%
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy utilizing Metronidazole
Number of subjects: 1265

Group type: COMPARATOR
Intervention: 24-hour antibiotic therapy utilizing Metronidazole (1.5 g) and/or Cefotaxime (4 g)
Number of subjects: 1265
Study: 75643

Group type: EXPERIMENTAL
Intervention: Virus isolation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescent staining (IF‐test)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tzanck smears
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of any two diagnostic methods
Number of subjects: 32

Group type: COMPARATOR
Intervention: IF‐test and Tzanck smear
Number of subjects: 32
Study: 30404085

Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy-enhanced SSE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naked-eye SSE
Number of subjects: 0
Study: 25267326

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention (EQUIP)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (untrained endoscopists)
Number of subjects: 1200
Study: 25800417

Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional behavioral couple therapy
Number of subjects: 134
Study: 21859315

Group type: COMPARATOR
Intervention: EPB (Control)
Number of subjects: 100

Group type: COMPARATOR
Intervention: DPB (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EPHF(9.5)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EPHF(5)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHF(9.5)P
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHF(5)P
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPHF(9.5)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DHF(5)P
Number of subjects: 100
Study: 19884554

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Gemcitabine and Carboplatin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: RRM1 protein levels
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: ERCC1 protein levels
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Model for response prediction including RRM1, ERCC1, and treatment arm
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: RRM1 and ERCC1 levels
Number of subjects: 170
Study: 17084905

Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducation and pharmacotherapy
Number of subjects: 38
Study: 15316128

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 11348951

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 283

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 283
Study: 9205823

Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 8240465

Group type: COMPARATOR
Intervention: ibuprofen/placebo (stomach) 0.9 ± 0.1
Number of subjects: 20

Group type: COMPARATOR
Intervention: ibuprofen/placebo (duodenum) 0.0 ± 0.0
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (stomach) 0.8 ± 0.1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (duodenum) 0.1 ± 0.1
Number of subjects: 20

Group type: COMPARATOR
Intervention: ibuprofen/placebo (duodenum) 0.2 ± 0.1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (stomach) 0.9 ± 0.1
Number of subjects: 20
Study: 2822066

Group type: EXPERIMENTAL
Intervention: Atracurium-induced intense neuromuscular blockade with halothane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atracurium-induced intense neuromuscular blockade with fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-tetanic count (PTC) method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) response
Number of subjects: 60
Study: 31548130

Group type: EXPERIMENTAL
Intervention: 4Kscore test followed by mpMRI
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Initial mpMRI followed by biopsy for negative mpMRI (PI-RADS 1-2) if the 4Kscore was >18% or PSAd was >0.10ng/ml/cm3
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: 4Kscore test
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: PSAd <0.10ng/ml/cm3
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ERSPC-RC <2%
Number of subjects: 266
Study: 29929375

Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Coronary Artery Ectasia (CAE)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Coronary Artery Ectasia (CAE) + AMI
Number of subjects: 119

Group type: COMPARATOR
Intervention: Coronary Heart Disease (control)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal Coronary Arteries (control)
Number of subjects: 119

Group type: COMPARATOR
Intervention: AMI patients without CAE (AMI group)
Number of subjects: 119
Study: 28226183

Group type: EXPERIMENTAL
Intervention: Self-management workshop for young people and parents
Number of subjects: 22
Study: 25801699

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 566
Study: 23631832

Group type: EXPERIMENTAL
Intervention: Automatic segmentation using iPlan software
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human observers
Number of subjects: 20
Study: 21334025

Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction followed by standard running vesicourethral anastomosis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard running vesicourethral anastomosis (control)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction
Number of subjects: 94
Study: 19050050

Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17007757

Group type: EXPERIMENTAL
Intervention: Oral steroid group (prednisolone 2mg/kg/day on alternate days, tapered over 8 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intra-lesional steroid group (triamcinolone 1 to 5 mg/kg, max 30mg, six injections monthly)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (managed conservatively with repeated hospital visits)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral steroid group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intra-lesional steroid group
Number of subjects: 75
Study: 15362027

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (50 mg daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: mesalamine (3 g daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 131
Study: 11493295

Group type: EXPERIMENTAL
Intervention: Silicone gel dressings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsilicone gel dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9923728

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Post treadmill exercise skill test
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Order by time effect for hematocrit
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Plasma glucose, plasma lactate, hemoglobin concentrations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Body mass
Number of subjects: 6
Study: 8063434

Group type: EXPERIMENTAL
Intervention: Test toothpaste containing the lactoperoxidase system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal fluoridated toothpaste
Number of subjects: 12
Study: 3057815

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31771385

Group type: COMPARATOR
Intervention: C+P (conventional carious lesion management with prevention)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: B+P (biological management with prevention)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: PA (prevention alone)
Number of subjects: 1144
Study: 29653527

Group type: EXPERIMENTAL
Intervention: Peer intervention based on the Theory of Planned Behavior (TPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29045105

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 60
Study: 25602891

Group type: EXPERIMENTAL
Intervention: Standard support communities receiving modest funding to implement Stepping On
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Enhanced support communities receiving funding and technical support
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control communities receiving no special resources or guidance on fall prevention
Number of subjects: 150
Study: 23880195

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy for 2 years
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Comparison of treatment groups
Number of subjects: 187
Study: 21071361

Group type: EXPERIMENTAL
Intervention: O+O (oral stimulation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: T/K+T/K (tactile/kinesthetic stimulation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: O+T/K (combined intervention)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 18186973

Group type: COMPARATOR
Intervention: CQ alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CQ-CP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CQ-PR
Number of subjects: 15
Study: 17010806

Group type: EXPERIMENTAL
Intervention: Active therapy with elastic bandage of the legs (compression pressure 40 to 60 mm Hg) and abdomen (compression pressure 20 to 30 mm Hg) for 10 min each.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham leg bandage and sham abdominal bandage.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Therapy with elastic compression stockings of the legs (prescribed in all patients).
Number of subjects: 21
Study: 12717396

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 72
Study: 9826312

Group type: EXPERIMENTAL
Intervention: Bosentan (1.0 g BID)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7522004

Group type: EXPERIMENTAL
Intervention: Argon green laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Krypton red laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both laser treatments
Number of subjects: 0
Study: 2681673

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 1084825

Group type: EXPERIMENTAL
Intervention: Sulindac 240 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin 4.8 gm
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31222344

Group type: EXPERIMENTAL
Intervention: High dietary intake of molybdenum (Mo) and cadmium (Cd)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose Mo and Cd co-treated group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination groups (Mo and Cd co-exposure)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Co-exposure groups (Mo and Cd)
Number of subjects: 60
Study: 29072167

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 8
Study: 23425313

Group type: EXPERIMENTAL
Intervention: Coordinated renal care network
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard renal care in nephrology departments
Number of subjects: 160
Study: 21555773

Group type: EXPERIMENTAL
Intervention: 20 µg of teriparatide once daily for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 24
Study: 19555809

Group type: EXPERIMENTAL
Intervention: L-arginine (1.5 g bid)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg qd) with L-arginine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17200474

Group type: EXPERIMENTAL
Intervention: Pexelizumab (2 mg/kg intravenous bolus prior to PCI followed by 0.05 mg/kg per hour infusion over 24 hours)
Number of subjects: 5745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 5745
Study: 15070948

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11453960

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (5 or 10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrocortisone responders
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrocortisone nonresponders
Number of subjects: 32
Study: 9622184

Group type: EXPERIMENTAL
Intervention: Attention biased towards left location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention biased towards right location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divided attention condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention biased towards left or right location
Number of subjects: 0
Study: 7912766

Group type: EXPERIMENTAL
Intervention: Virosome influenza vaccine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Commercial whole-virus vaccine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Subunit vaccine
Number of subjects: 126
Study: 2073959

Group type: EXPERIMENTAL
Intervention: Krill enzyme treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-enzymatic treatment
Number of subjects: 31
Study: 781227

Group type: EXPERIMENTAL
Intervention: Fenoprofen (400 mg Q6H)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Aspirin (1,000 mg Q6H)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 31562758

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib (300 mg b.i.d.; tablets)
Number of subjects: 154
Study: 28558366

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment in MDD patients with AIHM
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: MDD-AIHM
Number of subjects: 2811

Group type: COMPARATOR
Intervention: MDD
Number of subjects: 2811

Group type: COMPARATOR
Intervention: BD
Number of subjects: 2811
Study: 26091286

Group type: EXPERIMENTAL
Intervention: BR-TD-1001 (test vaccine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 50
Study: 23873290

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lithium + Valproate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lithium (coadministered with Valproate)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lithium only
Number of subjects: 75
Study: 21812168

Group type: EXPERIMENTAL
Intervention: Patient tracking/recall/outreach and provider prompts
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study: 19449015

Group type: EXPERIMENTAL
Intervention: Standard medical therapy for slow-transit constipation
Number of subjects: 7
Study: 16413699

Group type: EXPERIMENTAL
Intervention: Preradiotherapy treatment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Postradiotherapy treatment
Number of subjects: 210

Group type: COMPARATOR
Intervention: Patients with major deviations in treatment schedule
Number of subjects: 210

Group type: COMPARATOR
Intervention: Patients without major deviations in treatment schedule
Number of subjects: 210
Study: 16608381

Group type: EXPERIMENTAL
Intervention: Intravenous propionyl L‐carnitine 600 mg 3 times weekly for 12 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 14597928

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (TT)
Number of subjects: 302
Study: 10511934

Group type: EXPERIMENTAL
Intervention: Cooling PRK
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 38
Study: 7734254

Group type: EXPERIMENTAL
Intervention: Hyperbaric amethocaine 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-pregnant group
Number of subjects: 90

Group type: COMPARATOR
Intervention: First trimester group
Number of subjects: 90
Study: 2271747

Group type: EXPERIMENTAL
Intervention: 15 mg SR tablets after a high fat breakfast
Number of subjects: 28

Group type: COMPARATOR
Intervention: 15 mg SR tablets in fasted state
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 30 mg SR tablets 1 h before, 0.5 h after, 2 h after a high fat meal
Number of subjects: 28
Study: 399768

Group type: EXPERIMENTAL
Intervention: Functional assessments in hospital before discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional assessments at home shortly after discharge
Number of subjects: 0
Study: 31182442

Group type: EXPERIMENTAL
Intervention: Prescription support-tool
Number of subjects: 230

Group type: COMPARATOR
Intervention: No prescription support-tool (Control)
Number of subjects: 230
Study: 27764726

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both RE and AE
Number of subjects: 71
Study: 25879721

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 495
Study: 23599316

Group type: EXPERIMENTAL
Intervention: RRV-TV (tetravalent rotavirus vaccine)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 998
Study: 22052272

Group type: EXPERIMENTAL
Intervention: 75% mulberry extract oil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19660042

Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Abstinence with transdermal nicotine patch
Number of subjects: 78

Group type: COMPARATOR
Intervention: Abstinence with placebo
Number of subjects: 78

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 78
Study: 17228060

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Bladder training (BT)
Number of subjects: 164
Study: 14756910

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cream (CREAM)
Number of subjects: 12
Study: 18610663

Group type: EXPERIMENTAL
Intervention: Modified spirometry technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard FVC maneuver
Number of subjects: 72
Study: 9205940

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 96

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 96
Study: 8392288

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 3795326

Group type: EXPERIMENTAL
Intervention: Continuous therapy with mebendazole (1800 mg day-1 for 18 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interrupted therapy with mebendazole (1800 mg day-1 for interrupted 6-week courses for a minimum of three courses, with intervals of 19-22 weeks)
Number of subjects: 10
Study: 29648532

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) tablet of repaglinide/metformin (2/500 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Equivalent doses of individual (EDI) tablets of repaglinide (2 mg) and metformin (500 mg)
Number of subjects: 50
Study: 31833938

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30620666

Group type: EXPERIMENTAL
Intervention: Whole-body higher-repetition RT (20-25 repetitions/set to failure at ∼30%-50% 1RM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lower-repetition RT (8-12 repetitions/set to failure at ∼75%-90% 1RM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 40
Study: 28635236

Group type: EXPERIMENTAL
Intervention: Xiaoaiping combined with S‐1 and cisplatin
Number of subjects: 124

Group type: COMPARATOR
Intervention: S‐1 and cisplatin
Number of subjects: 124
Study: 26431653

Group type: EXPERIMENTAL
Intervention: Chinese drug iontophoresis
Number of subjects: 296

Group type: COMPARATOR
Intervention: Medium frequency electrotherapy
Number of subjects: 296
Study: 23221572

Group type: EXPERIMENTAL
Intervention: High-protein diet (30% of energy from protein)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal-protein diet (15% of energy from protein)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-protein diet (5% of energy from protein)
Number of subjects: 79
Study: 21477901

Group type: EXPERIMENTAL
Intervention: Sterol fortified orange juice (1g/240 ml juice twice a day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sterol fortified OJBev (1g/240 ml beverage twice a day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo OJ
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo OJBev
Number of subjects: 72